1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Taiwan Advance Bio-Pharmaceutical, Inc.

Taiwan Advance Bio-Pharmaceutical, Inc.

TTPEX:4186
7.10
TWD
-0.19
(-2.61%)
909.00MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.89
2.49
2.7
2.04
2.39
2.5
2.72
2.91
2.7
3.54
3.51
3.94
4.05
- -
Basic EPS, GAAP
0.32
-1.76
-1.79
-1.74
-1.62
-1.98
-2.3
-1.07
-1.32
0.04
-0.12
0.25
0.31
- -
Free Cash Flow per Basic Share
-2.07
-2.54
-2.78
-2.15
-1.81
-2.73
-2.68
-1.31
-0.69
-0.31
0.01
0.05
0.22
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
7.32
5.56
3.81
3.79
2.17
2.4
2.42
3.99
2.68
2.72
2.6
2.85
3.17
2.98
Tangible Book Value per Share
7.28
5.52
3.78
3.76
2.15
2.18
2.04
3.72
2.57
2.68
2.6
2.85
3.17
2.98
Basic Weighted Avg Shares
57
57
56
59
61
67
76
81
90
90
90
90
90
90
Sales/Revenue/Turnover
163
141
151
120
145
168
206
236
243
318
316
354
365
- -
Operating Margin (%)
-50.82
-84.47
-86.12
-108.56
-71.57
-91.29
-75.3
-35.85
-42.24
2.64
1.35
12.66
10.25
- -
Depreciation Expense
14
16
19
20
21
22
35
34
30
28
26
21
20
- -
Net Income, GAAP
18
-100
-100
-102
-98
-133
-175
-86
-119
3
-11
23
28
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
13.98
- -
- -
- -
- -
Profit Margin (%)
11.11
-70.8
-66.23
-85.19
-67.84
-79.12
-84.87
-36.67
-48.7
1
-3.38
6.46
7.69
- -
Working Capital
119
-4
-99
-17
-74
-24
37
131
23
17
-58
-10
-5
-5
LT Debt
28
25
22
12
24
124
156
127
116
108
87
61
66
77
Total Equity
414
314
215
231
133
170
195
359
241
245
234
256
285
268
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.27
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.64
- -
- -
- -
- -
Return on Common Equity (%)
4.49
-27.38
-37.77
-45.8
-54.04
-88.05
-95.72
-31.18
-39.49
1.3
-4.46
9.33
10.36
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
208
207
222
LT Borrowings
50
62
73
LT Finance Leases
3
3
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
90
90
90
Market Capitalization
1,030
1,004
909

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
237
267
276
Cash, Cash Equivalents & STI
114
141
158
Accounts Receivable, Net
90
93
86
Inventories
21
21
22
Total Current Liabilities
265
272
281
Payables & Accruals
- -
- -
- -
ST Debt
208
207
222
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.65%
-3%
11.17%
Free Cash Flow
70.72%
141.72%
352.74%
Net Income, GAAP
-77.96%
-158.8%
22.61%
Sales/Revenue/Turnover
10.15%
9.69%
3%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
354
2025
- -
- -
365
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.25
2025
- -
- -
0.31
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wen Lung Su
Full Time Employees
160
Sector
Health technology
Industry
Medical specialties
Address
No. 25, Kangning Street Taipei TP Taiwan 22180
IPO Date
Nov 27, 2012
Website
biotest.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Taiwan Advance Bio-Pharmaceutical Inc. (Ticker: 4186.TWO) is a biopharmaceutical company primarily engaged in the research, development, manufacturing, and sale of innovative biological drugs and biosimilars. Its core products and services include recombinant protein drugs, monoclonal antibodies, vaccine development, and contract manufacturing services for biopharmaceuticals. The company specializes in therapeutic categories such as oncology, autoimmune diseases, and infectious diseases. It offers products under various proprietary brand names and custom drug formulations for both domestic and international markets. The company operates chiefly out of its headquarters in Taipei, Taiwan, with manufacturing and R&D facilities serving markets in Asia and expanding globally. Founded in 2012, Taiwan Advance Bio-Pharmaceutical has established itself as a key player in Taiwan’s biotechnology sector. In recent developments over the last one to two years, Taiwan Advance Bio-Pharmaceutical has entered into strategic partnerships with global biopharmaceutical firms to enhance its drug pipeline and broaden market reach. The company has also expanded its production capabilities through facility upgrades and has launched new biosimilar products aimed at treating chronic and severe conditions, underlining a strategic shift towards diversifying its portfolio and increasing global competitiveness. Additionally, Taiwan Advance Bio-Pharmaceutical has increased investment in biologics contract development and manufacturing organization (CDMO) services to leverage growing demand in the biologics market. The company operates within the biotechnology and pharmaceutical industry segments, targeting hospitals, healthcare providers, and pharmaceutical distribution channels. It maintains a focus on high-quality biotechnological products and drug development services, including biosimilars, innovative biologics, and vaccine candidates, contributing to its sustainable growth and international partnerships. It remains an independent entity, driving innovation from Taiwan with ambitions for global expansion in cutting-edge biopharmaceuticals.